Miragen Therapeutics, Inc. (NASDAQ:MGEN) is trending higher in the market today as the company shares are trading 5.48% or 0.12 points up from last closing price of $2.19, reaching $2.31 at last check. Any clue why there is so much of action in the MGEN stock? The share price has risen in 3 of the last 5 days and is down -19.49% over the past week. It will be exciting to see whether the stock manages to continue increasing or take a minor break for the next few days. The move came on weak volume too with far less shares changing hands than in a normal session. Trading activity as of this writing weakened by -34,855 shares, and in total 187145 shares valued at $432305 were seen changing hands compared with 222000 shares valued at $486180 recorded at the previous session. You should take into consideration that a falling volume on higher prices causes divergence and may be an early warning about possible changes in MGEN stock for the next couple of days.
Miragen Therapeutics, Inc. (MGEN) shares have notched a 3-month decline of about -19.49%, but has still tumbled -27.72% year to date. By comparison, the stock sank -69.75% over the past 12 months, while it slipped -23.16% over the 1 month. The company’s market cap is around $64.85M, with its short interest ratio standing at 8.96%.
In the current trading session for MGEN, the stock witnessed two major price actions, it rose to a high of $2.39 and was down as much as $2.1735 at one point. The high recorded is very low when compared to their 52-week high which is $2.01. The 52-week high is now at -70.34 distance from current price. Their recent low of $7.94 represents a 17.16% recovery. This data is quite important for investors who look to benefit from the recent rise of the company’s stock. The price target currently for MGEN is $15.1, this is above the recent high that the stock attained. Taking a look at the overall sentimental views of financial analysts, the trading pattern of this stock recently is very clear.
The stock of Miragen Therapeutics, Inc. earned $-1.29 per share in the trailing 12 months and has a P/E ratio of -1.79. You can compare it with that of similar companies in its industry to get a sense of whether the stock you’re looking to purchase is overvalued or undervalued. Its current price to earnings ratio is lower than the ones recorded by the industry which is 105.27 and lower compared to the sector’s average of 37.46. When the P/E ratio is low let’s say below 1.0, then the stock price is considered a good value. MGEN also has P/S multiple of 17.1. This is smaller versus the 12 month P/S ratios of other companies in the same indutry. The peer average price to sales ratio is 43.04x.
The company recorded an interesting insider purchase transaction by the Director on Oct 11, 2018. A Securities and Exchanges Commission filings show that Thomas E Hughes bought a total of 10,000 MGEN shares that day for a sum of around $47,700. The filings show that the insider stake has now grown to 12,827 shares, currently worth $29,630. Miragen Therapeutics, Inc. (MGEN) insiders have acquired no shares in the stock within the past three months. The total insider sales reported to the SEC in that time frame amounted to shares. In total, individual insiders traded no shares in the business, which makes up 0% of 10,000 shares that were traded over a year. In the past 12 months, insiders have purchased 10,000 shares while the seller parted with shares.
MGEN‘s last price was down -33.59% as compared to the average trading price of 50 days recorded at $3.48 while enlarging the period to 200 trading days, the average closing price was $2.69. At present, there are 29.61 million in the total number of common shares owned by the public and among those 27.64 million shares have been available to trade. The percentage of shares being held by the company management was 10.65% while institutions stake was 45.2%. The company has generated negative returns on equity over the last 12 months (-71.9%). It managed to keep its gross profit margin at 0% over the past 12 months.
When assessing the full upside of the MGEN stock, there is another set of technicals that should be looked into and considered. Its -6.19% decline from moving average of $2.46 has brought about a negative sentiment when calculated over the last 20 days. The market has allocated a beta of 1.28 to the stock. With the beta been greater than one, this implies that the company shares are theoretically more volatile than the market, something that the traders definitely are keeping an eye on.
Most of the analysts surveyed by Thomson/First Call think quite highly of Miragen Therapeutics, Inc. — 3 analysts rate the stock as a buy with another 0 rating it strong buy. There are 0 analysts who maintain a hold rating for the stock, with 0 giving it a sell rating. Analysts arrived at a 12-month price target of $21.25 on shares of Miragen Therapeutics, Inc. (NASDAQ:MGEN), which corresponds to 815.95% upside potential than its current market price of $2.31 and implies potential despite the recent advance in the price. However, their current target price has fallen from $21.25 a month ago and is up handily from the consensus target of $16.625 a quarter ago.
In the last five years, the EPS of the company has been roughly 36.2%. Though the percentage looks encouraging, extra headwinds are emerging as looking out over a next 5-year period, with analysts estimating that their earnings will decrease annually by 0%. The revenue of the company has risen at an average annualized rate of about 14.2 over the last five years. The company recently recorded a drop of -91.7%, but this figure is rather unattractive.
Let’s briefly check the hedge fund interest towards MGEN stock. Morgan Stanley added position in the company after it grew 471.1% or 9,350 shares of its common stock. The hedge fund now owns 53,398 shares worth $123,349, SEC documents show. Renaissance Technologies LLC cut assets in the stock as 159056 shares have been sold, reducing its stake by -8.9% to 144,900 shares which are currently valued at $334,719. In addition, State of Wisconsin Investment Board recently reported that it now owns 35,400 shares making a total of $81,774 based on the recent price. This refelects a change of 18.6% in their ownership.